International: +1-347-960-6455
Various Strategic Advancements in Drug Development are Beholding the Growth of Peanut Allergy Therapeutics Pipeline

According to a new research report “Peanut Allergy Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, peanut allergy therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

Peanut Allergy Therapeutics Pipeline Insights

Peanuts can cause a severe life-threatening allergic reaction, which is referred to as peanut allergy. This type of allergy is one of the most common cause of food allergy, which occurs when immune system reacts to protein found in peanuts. Casual skin contact can trigger the allergy if the affected area then touches the eyes, nose or mouth. Some of the commonly occurring symptoms of the allergy include constriction of airways resulting in anaphylaxis, sudden and extreme drop in blood pressure, difficulty in breathing due to swelled throat, dizziness, lightheadedness, digestive problems, itching or tingling in or around the mouth and throat, runny nose, and unconsciousness. Age, past allergy to peanuts, other food allergies, family history, and atopic dermatitis are some of the risk factors of the peanut allergy.

The allergy can also be triggered by even a little exposure to peanuts in form of oil sprays or contact with peanut butter. The disease can be diagnosed by skin test, blood test, maintaining a food diary, and elimination diet. There is no approved medication for the treatment of peanut allergy, however, healthcare provider may prescribe medication to reduce the symptoms and effects of the allergy. Furthermore, researchers are evaluating long-term safety and efficacy of oral immunotherapy to treat the allergy.

Insights into Pipeline Segments

According to the research findings, majority of the pipeline drug candidates are being developed to be administered through intravenous route. It has been observed that the intravenous route of medication is convenient and provides improved patient’s compliance. Administration of therapeutics through intravenous route has also shown promising results in clinical studies.

Positive Clinical Trial Results are Expected to Drive Peanut Allergy Therapeutics Pipeline

Companies that are involved in developing therapeutics for peanut allergy have shown positive clinical results in the various phases of drug development. For instance, in March 2019, Aimmune Therapeutics Inc. announced positive phase III clinical trial result of AR101, which is an oral immunotherapy for peanut allergy. As per the results of the study, AR101 met the primary endpoints of the trial and exhibited a consistent safety profile. Also, no cases of anaphylaxis or eosinophilic esophagitis were observed.

Designation Grant Plays a Vital Role in Accelerating the Drug Development Process

The Food and Drug Administration (FDA) granted Aimmune Therapeutics Inc.’s AR101 Fast Track Designation for peanut allergy in September 2014 and Breakthrough Therapy Designation for peanut allergy in patient ages 4–17 years in June 2015. Therefore, with the increasing number of designation grants, the overall peanut allergy therapeutics pipeline is expected to grow significantly in the upcoming years.

Strategic Advancements Play a Pivotal Role in the Peanut Allergy Therapeutics Development

Companies are collaborating to expand their product portfolio and geographical footprint. For instance, in October 2017, Aimmune Therapeutics Inc. entered into a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi-aventis Groupe to study AR101 in combination with dupilumab for the treatment of patients with peanut allergy.

Browse report overview with detailed TOC on "Peanut Allergy Therapeutics – Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:

Inimmune, ImmusanT Inc., Aimmune Therapeutics Inc., DBV Technologies S.A., AllerGenis, Inc., and AnaptysBio Inc. are some major players working for the development of therapeutics of peanut allergy.

Peanut Allergy Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of peanut allergy. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the peanut allergy therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to peanut allergy.